secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001104659-24-061958
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech Q1 net loss narrows to $17.7M; FDA accepts DFD-29 NDA for rosacea
--------------------------------------------------------------------------------

- Consolidated net revenue $13.0M, all from dermatology products, up 7% YoY driven by Qbrexza and Accutane.
- Net loss attributable to common stockholders $(17.7)M ($1.03/share) vs $(23.5)M ($3.47/share) in Q1 2023.
- Cash and equivalents $85.8M as of March 31, up from $83.4M; includes $11M January direct offering.
- FDA accepted DFD-29 NDA with PDUFA date Nov 4, 2024; potential only oral therapy for rosacea lesions and erythema.
- Triplex CMV vaccine Phase 2 for HIV/CMV fully enrolled; topline data Q4 2024; liver transplant trial dosed first patient.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000110465924061958/0001104659-24-061958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000110465924061958/tm2414584d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-061958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer